• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Avian influenza activities at CSIRO?s Australian Animal Health Laboratory

Sally Furniss

Well-known member
Avian influenza activities at CSIRO?s Australian Animal Health Laboratory

CSIRO?s Australian Animal Health Laboratory performs two vital functions to prevent avian influenza from spreading in birds ? disease diagnosis and research.Rapid diagnosis

The Australian Animal Health Laboratory (AAHL) plays a vital role in maintaining Australia?s capability to quickly diagnose exotic (foreign) and emerging animal diseases.
The facility is a world animal health organisation, the Office Internationale des Epizooties (OIE), regional reference laboratory for the highly pathogenic avian influenza, able to safely handle the virus under biocontainment.
AAHL receives diagnostic samples from across Australia and throughout the South-East Asian region.
Current staffing and equipment provides AAHL with the capacity to undertake diagnosis and testing throughout a major animal disease outbreak. This capacity is being strengthened.
AAHL is an OIE reference laboratory for avian influenza and a Food and Agriculture Organisation (FAO) reference centre.
AAHL's new Diagnostic Emergency Response Laboratory (DERL) should be operational in 2008.
This high-throughput laboratory will enhance AAHL?s surge capacity, enabling it to process more samples, much faster.

Test development

With funding from the Australian Biosecurity Cooperative Research Centre, CSIRO researchers have developed an avian influenza virus type A and subtype H5-specific real-time reverse transcription Polymerase Chain Reaction (PCR) for detection of Asian H5N1 isolates.
Research is continuing to ensure rapid detection of other avian influenza strains and to transfer the test to veterinary diagnostic laboratories throughout the region.

Commercial testing

In biocontainment, CSIRO researchers are testing a range of commercial products, including vaccines and antivirals, for Australian and overseas clients.
We are assessing the ability of these products to inactivate the avian influenza virus and provide birds with protection.

Disease simulation exercises

AAHL was involved in Exercise Eleusis, a national exercise simulating a zoonotic disease outbreak of avian influenza, which was held in November/December 2005.
AAHL is also participating in Exercise Hippolytus - an 18-month national program of workshops and exercises addressing emergency animal disease outbreaks and animal health laboratories.

Avian influenza research

AAHL offers a unique combination of expertise in virology, immunology and biosecure animal facilities to facilitate pathogenesis studies. We have conducted trials using animal species including:
  • chickens
  • ducks
  • ferrets
  • mice.
A closer understanding of the host-pathogen response to avian influenza will help us to develop better control strategies for this and other diseases that threaten Australia's biosecurity.
In 2007 a CSIRO team, led by Dr John Lowenthal, began a five-year research project, funded by Advanced Technology Services Australia, investigating gene silencing based strategies for protecting poultry against influenza.
During 2006-07, AAHL hosted Professor Ton Schat from Cornell University, USA.
He investigated the disease-causing potential of a mutated form of H5N1 and initiated studies to compare the susceptibility of chickens and ducks to H5N1 infection.
Other AAHL research, in collaboration with the University of Melbourne, Victoria, Australia, and CSL Limited, aims to increase the amount of influenza vaccine that is produced in eggs.
The project, led by Dr Andrew Bean, investigates factors including the type of poultry egg used, the virus dose and timing in order to increase the virus titre.

Overseas assistance

AAHL?s regional program led by Dr Peter Daniels is assisting neighbouring South-East Asian countries in their efforts to control and eradicate highly pathogenic avian influenza.
Activities include:
  • isolate characterisation and sequence analysis
  • support to implement Indonesia's National Strategic Plan for AI control and human pandemic preparedness
  • projects building veterinary laboratory capacity - Indonesia and Vietnam
  • a project in Indonesia to improve AI control in commercial poultry
  • a project with Indonesia and Vietnam investigating the natural history and epidemiology of H5N1 infection in ducks
  • developing web-enabled networking of Indonesia's laboratory information management system.
http://www.csiro.au/science/AIatAAHL.html
 
Re: Avian influenza activities at CSIRO?s Australian Animal Health Laboratory

CSIRO opens rapid response animal disease centre

Reference: 08/121
The Federal Minister for Industry, Innovation, Science and Research, Senator the Hon Kim Carr, officially opened CSIRO Livestock Industries? Diagnostic Emergency Response Laboratory (DERL) at the Australian Animal Health Laboratory (AAHL) in Geelong today.
23 July 2008
"The new ?state of the art? laboratory will be able to process more samples, faster, in the event of an emergency animal disease outbreak, and will be located within the AAHL?s advanced high biocontainment facility," Senator Carr said.
"AAHL?s core responsibility is to respond to outbreaks of emergency animal diseases such as foot and mouth disease or equine influenza. The emergency response laboratory gives the Government further confidence that AAHL and the nation will be ready to detect and quickly respond to even the worst such outbreaks.
"The new high-throughput testing laboratory will play a dual role at AAHL. During ?routine mode?, when there is no emergency animal disease outbreak, the laboratory will continue to function as a core diagnostic area, an area for test development and validation and for predictive biomodelling activities.
?The new ?state of the art? laboratory will be able to process more samples, faster, in the event of an emergency animal disease outbreak, and will be located within the AAHL?s advanced high biocontainment facility," Senator Carr said.

"In the face of an outbreak the laboratory will become an assembly line for samples and will enable AAHL staff to perform serology tests on up to 10,000 samples per day, with maximum biosecurity.
"Australia?s outbreak of equine influenza in August 2007 demonstrated the need for a high throughput laboratory in Australia,? Senator Carr said.
?Last year Australia faced the major challenge of eradicating equine influenza. Following comprehensive national and state disease control and surveillance programs Australia is provisionally free from equine influenza.
?Although the focus in recent months has been on equine influenza, foot-and-mouth disease is still considered the greatest threat to Australia?s livestock industries.?
AAHL is a world leading research facility and since its establishment has been involved in a number of significant discoveries, including the identification of the paramyxovirus Hendra virus in 1994.
In the last five years more than A$55 million has been invested into AAHL from the Australian Government and external revenue to ensure the facility continues to operate as one of the world?s leading high biocontainment laboratories.


http://www.csiro.au/news/RapidResponseLab.html
 
Back
Top